ABSTRACT
Abciximab Observational outcome studies1-5 have invariably shown that abciximab, the prototype glycoprotein (GP) IIb/IIIa inhibitor, as adjunctive therapy to infarcted artery stenting provide a significant decrease in the incidence of major cardiac adverse events that is not attributable exclusively to the reduction of ischemic events related to target vessel failure. On the contrary, concluded randomized trials comparing stenting alone with stenting plus abciximab have produced conflicting results,6-10 and the largest study – the CADILLAC trial – did not show any benefit of abciximab as adjunctive treatment to infarcted artery stenting.
